A Human Immunodeficiency Virus Superinfection Diagnosed in a Patient on Intramuscular Long-acting Combination of Cabotegravir and Rilpivirine

Nadia Valin; Sidonie Lambert-Niclot; Emma Torres; Jean Luc Meynard; Claire Périllaud-Dubois; Laurence Morand-Joubert; Karine Lacombe

doi:10.1093/cid/ciad757

A Human Immunodeficiency Virus Superinfection Diagnosed in a Patient on Intramuscular Long-acting Combination of Cabotegravir and Rilpivirine

Clin Infect Dis. 2024 Mar 21:ciad757. doi: 10.1093/cid/ciad757. Online ahead of print.

Authors

Nadia Valin¹, Sidonie Lambert-Niclot², Emma Torres¹, Jean Luc Meynard¹, Claire Périllaud-Dubois², Laurence Morand-Joubert², Karine Lacombe^{1

3}

Affiliations

¹ Department of Infectious and Tropical Diseases, Saint Antoine Hospital, Paris, France.
² Virology Department, Sorbonne University, Saint-Antoine Hospital, AP-HP, Pierre Louis Epidemiology and Public Health Institute (iPLESP), INSERM 1136, Paris, France.
³ Pierre Louis Institute of Public Health, Sorbonne Université, Inserm UMR-S1136, Paris, France.

PMID: 38513236
DOI: 10.1093/cid/ciad757

Abstract

A case of a male with human immunodeficiency virus with plasma genotyping detecting no resistance and a CRF02_AG subtype had a controlled HIV RNA on antiretroviral therapy since 2010. We introduced intramuscular therapy with cabotegravir and rilpivirine. One month later, his HIV RNA was 1500 copies/mL; genotyping found a subtype B with many mutations.

Keywords: HIV; cabotegravir; genotyping; long-acting injectable therapy; rilpivirine.

© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.